JP2005508338A5 - - Google Patents

Download PDF

Info

Publication number
JP2005508338A5
JP2005508338A5 JP2003532004A JP2003532004A JP2005508338A5 JP 2005508338 A5 JP2005508338 A5 JP 2005508338A5 JP 2003532004 A JP2003532004 A JP 2003532004A JP 2003532004 A JP2003532004 A JP 2003532004A JP 2005508338 A5 JP2005508338 A5 JP 2005508338A5
Authority
JP
Japan
Prior art keywords
immunoglobulin
use according
composition
route
antacid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003532004A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508338A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/033322 external-priority patent/WO2003028668A2/en
Publication of JP2005508338A publication Critical patent/JP2005508338A/ja
Publication of JP2005508338A5 publication Critical patent/JP2005508338A5/ja
Pending legal-status Critical Current

Links

JP2003532004A 2001-10-04 2002-10-04 免疫性疾患を処置するためのガンマグロブリンの使用 Pending JP2005508338A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32704301P 2001-10-04 2001-10-04
US38096002P 2002-05-16 2002-05-16
PCT/US2002/033322 WO2003028668A2 (en) 2001-10-04 2002-10-04 Gammaglobulin treatment of immune disorders

Publications (2)

Publication Number Publication Date
JP2005508338A JP2005508338A (ja) 2005-03-31
JP2005508338A5 true JP2005508338A5 (enExample) 2006-01-05

Family

ID=26985697

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003532004A Pending JP2005508338A (ja) 2001-10-04 2002-10-04 免疫性疾患を処置するためのガンマグロブリンの使用

Country Status (6)

Country Link
US (1) US20030099635A1 (enExample)
EP (1) EP1463527A4 (enExample)
JP (1) JP2005508338A (enExample)
CA (1) CA2462682A1 (enExample)
MX (1) MXPA04003156A (enExample)
WO (1) WO2003028668A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003222141A1 (en) * 2002-03-29 2003-10-13 Repligen Corporation Ctla4 compositions in the treatment of autism
US20090280114A1 (en) * 2002-04-12 2009-11-12 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2006014911A2 (en) * 2004-07-26 2006-02-09 Kossor David C Treatment of inflammatory, autoimmune, or other disorders, using agents that reduce the sequestering of zinc by calprotectin
JP2007284351A (ja) * 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
US20060205012A1 (en) 2004-12-09 2006-09-14 Meso Scale Technologies, Llc Diagnostic test
PT2289909E (pt) 2005-11-30 2015-02-10 Abbvie Inc Método de rastreio, processo de purificação de globulómeros a-beta não difundíveis, anticorpos selectivos contra os referidos globulómeros a-beta não difundíveis e processo para o fabrico dos referidos anticorpos
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US7968293B2 (en) 2007-08-13 2011-06-28 Baxter International Inc. IVIG modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease
US20100158893A1 (en) * 2008-12-19 2010-06-24 Baxter International Inc. Systems and methods for obtaining immunoglobulin from blood
WO2010128265A2 (fr) * 2009-05-07 2010-11-11 Stallergenes S.A. Utilisation d'immunoglobulines igg1 et/ou de ligands du récepteur cd32 pour le traitement de maladies et manifestations inflammatoires par voie mucosale
EP2762492A3 (en) 2009-05-27 2015-03-18 Baxter International Inc A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
CN105727286A (zh) * 2010-04-23 2016-07-06 普若拜特有限公司 药用组合物
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
EP3597220A1 (en) 2013-02-26 2020-01-22 Baxalta GmbH Treatment of central nervous system disorders by intranasal administration of immunoglobulin g
JP6424210B2 (ja) 2013-05-06 2018-11-14 バクスアルタ インコーポレイテッド プールされた免疫グロブリンｇを用いたアルツハイマー病の亜集団の治療
US10478493B2 (en) 2015-08-31 2019-11-19 Stolle Milk Biologics, Inc. Method of treating protozoal gastrointestinal disorders in immunocompromised patients
ES2690178A1 (es) * 2017-05-18 2018-11-19 Apc Europe Slu Plasma de animal o fracciones del mismo para su utilización en el tratamiento de trastornos de deterioro cognitivo en seres humanos y animales de compañia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE33565E (en) * 1978-02-06 1991-04-02 Stolle Research And Development Corporation Prevention and treatment of rheumatioid arthritis
US4477432A (en) * 1981-05-01 1984-10-16 Cutter Laboratories, Inc. Oral immune globulin
US4897265A (en) * 1983-10-27 1990-01-30 Stolle Research & Development Corporation Method for treating disorders of the vascular and pulmonary systems
US5242691A (en) * 1982-06-03 1993-09-07 Stolle Research & Development Corporation Anti-inflammatory factor, method of isolation, and use
US5106618A (en) * 1987-07-02 1992-04-21 Stolle Research And Development Corporation Method of treating protozoal gastrointestinal disorders by administering hyperimmune milk product
JPH06508371A (ja) * 1991-06-21 1994-09-22 ユニバーシティー オブ シンシナティ 経口投与できる治療用タンパク質及びその製法
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5455160A (en) * 1993-05-27 1995-10-03 Fagerhol; Magne K. Diagnostic test and kit for disease or disorders in the digestive system
US5681571A (en) * 1993-10-08 1997-10-28 Duotol Ab Immunological tolerance-inducing agent
US6090380A (en) * 1994-01-12 2000-07-18 Research Corporation Technologies, Inc. Treatment of rheumatoid arthritis by oral administration of pooled human immunoglobulin
JPH10212246A (ja) * 1997-01-30 1998-08-11 Nippon Zoki Pharmaceut Co Ltd 経口投与用製剤
JP2002501616A (ja) * 1997-05-19 2002-01-15 リプリゲン コーポレーション 自閉的症候群を鑑別診断および治療する際の助けとするための方法
US20020114802A1 (en) * 1998-02-10 2002-08-22 Tjellstrom Bo Arthur Einar Oral immunoglobulin treatment for inflammatory bowel disease
WO1999057152A1 (en) * 1998-05-07 1999-11-11 Research Corporation Technologies, Inc. Oral administration of immunoglobulins for treating autoimmune hearing loss
AU5583799A (en) * 1998-08-25 2000-03-14 Human Genome Sciences, Inc. 49 human secreted proteins
CA2370268A1 (en) * 1999-04-19 2000-10-26 Richard Weisbart Treatment of adult rheumatoid arthritis by oral administration of pooled human immunoglobulin and an antacid
US6187309B1 (en) * 1999-09-14 2001-02-13 Milkaus Laboratory, Inc. Method for treatment of symptoms of central nervous system disorders

Similar Documents

Publication Publication Date Title
JP2005508338A5 (enExample)
UA41995C2 (uk) Лікарська форма азитроміцину з контрольованим вивільненням ( варіанти ), спосіб її введення, спосіб її виготовлення і спосіб лікування інфекційних захворювань ссавців з її використанням ( варіанти )
WO2006059108A3 (en) ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
CY1118849T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
CA2066403A1 (en) Transmucosal dosage form
JP2015512406A5 (enExample)
JP2004504406A5 (enExample)
CA2431565A1 (en) Pharmaceutical compositions based on anticholinergics and ciclesonide
JP2007523091A5 (enExample)
JP2002528502A5 (enExample)
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
RU2005126412A (ru) Сор1 для лечения воспалительных заболеваний кишечника
BR9813213A (pt) Composições orais de levosimendan
JP2002524415A5 (enExample)
JP2006516571A5 (enExample)
JP2024152860A5 (enExample)
JP2005508963A5 (enExample)
Sheoran Buccal drug delivery system: A review
CA2401000A1 (en) Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
JP2005525329A5 (enExample)
JPS6345218A (ja) Ｄ―フェンフルラミン含有うつ病用医薬組成物
JP2002540148A5 (enExample)
JP2001518481A (ja) 経口投与のためのセロトニン含有製剤及びその使用方法